Assessment of Relative Contributions of Fibrinolysis and Fibrinogenolysis to the Abnormalities of Plasma Fibrinogen/Fibrin-Retated D and E Antigens and Their Ratio in Liver Cirrhosis

Abstract

Many pathogenic mechanisms play a part in hemorrhage in chronic liver disease. This study was done to characterize the alterations of fibrinogen components and dysfibrinogenemia in patients with liver cirrhosis. Plasma from 31 patients with liver cirrhosis was analyzed to determine the fibrinogen/fibrin-related D and E antigens by latex photometric immunoassay; fibrinogen by the Clauss method; fibrinogen degradation product (FgDP), protein C antigen, and tissue plasminogen activator (tPA) by enzyme immunoassay; and antithrombin III by the colorimetric method, respectively. Reptilase, time and fibrin monomer (FM) tests were also done. Fibrinogen/fibrin-related D and E antigens were higher and their ratio (D/E) was lower in liver cirrhosis compared with normal subjects. Fibrinogen levels were inversely correlated with D (p = 0.0001) and E (p = 0.0001) antigenic levels in plasma. FgDP levels were not significantly correlated with D and E levels. However, semiquantitative D-dimer levels had significant association with D and E levels. Reptilase time was abnormally prolonged in all patients with high D and E levels, and FM tests were also positive in most patients with increased levels of D and E. Protein C antigen levels were inversely correlated with D (p = 0.0110) and E (p = 0.0112) concentrations but were well correlated with clottable fibrinogen concentrations (p = 0.0058). Hypercoagulability followed by pathologic activation of fibrinolysis, rather than synthesis of abnormal fibrinogen molecules, may contribute to hemorrhage. Not only true hypofibrinogenemia due to the decreased synthesis of intact fibrinogen but also elevated levels of these antigens may be clinically significant in the treatment of cirrhotic patients at risk of bleeding. Protein C may play an important regulatory role in fibrinolysis.

Keywords

Liver cirrhosis—Dysfibrinogenemia—Fibrinogen/fibrin degradation products— Fibrinolysis—Fibrinogenolysis.

Get full access to this article

View all access options for this article.

References

Mammen EF

Coagulation abnormalities in liver disease. Hematot Oncol

Clin North Am. 1992;6:1247.

Coccheri S. , Mannucci PM , Palareti G. , et al. Significance of fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis. Br J Haematol 1982;52:503.

Straub PW Diffuse intravascular coagulation in liver disease. Semin Thromb Hemost 1977;4:29.

Blanchard RA , Furie BC , Jorgensen M. et al. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981;305:242.

Green G. , Thomson JM , Dymock IW , et al. Abnormal fibrin polymerization in liver disease. Br J Haematol 1976;34:427.

Francis JL , Armstrong DJ Acquired dysfibrinogenemia in liver disease. J Clin Pathol 1982;35:667.

VanDeWater L. , Carr JM , Aronson D. , et al. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease . Blood 1986;67:1468.

Koppert PW , Huipers W. , Hoegeed NB , et al. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma. Thromb Haemost 1987;57:25.

Koppert PW , Koopman J. , Harverkate F. , et al. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant in degradation products of fibrin and fibrinogen. Blood 1986;68:437.

10.

Hersch SL ; Kunelis, T. , Francis RB The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987 ;69: 1315.

11.

Carr JM Disseminated intravascular coagulation in cirrhosis. Hepatology 1989;10:103.

12.

Verstraete, M. , Vermylen J. , Collen D. Intravascular coagulation in liver disease . Annu Rev Med 1974;25:447.

13.

Coccheri S. , Palareti G. , Dalmonte PR , et al. Investigations on intravascular coagulation in liver disease: soluble fibrin monomer complexes in liver cirrhosis. Haemostasis 1979; 8:8.

14.

Bick RL Hemostasis in liver and renal disease. ln: Disorders of thrombosis and hemostasis . Chicago: ASCP Press. 1992:175.

15.

Kruskal JB , Robson SC , Franks JJ , et al. Elevated fibrin-related and fibrinogen-related antigens in patients with liver disease. Hepatology 1992;16:920.

16.

Whitaker AN , Elms MJ , Masci PP , et al. Measurement of crosslinked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol 1984;37:882.

17.

Koopman J. , Haverkate F. , Koppert P. , et al. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using monoclonal antibody. J Lab Clin Med 1987; 109:75.

18.

Kroneman H. , Nieuwenhuizen W. , Knot EA , et al. Correlation between plasma levels of fibrin(ogen) derivatives as quantified by different assays based on monoclonal antibodies. Thromb Res 1991;61:441.

19.

Paramo JA , Rifon J. , Fernandez J. , et al. Thrombin activation and increased fibrinolysis in patients with chronic liver disease. Blood Coagul Fibrinolysis 1991;2:227.

20.

Takahashi H. , Tatewaki W. , Wada K. , et al. Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation. Thromb Haemost 1990;63:340.

21.

Takahashi H. , Tatewaki W. , Wada K. , et al. Fibrinolysis and fibrinogenolysis in liver disease. Am J Hematot 1990;34:241.

22.

Ferro D. , Quintarelli C. , Saliola M. , et al. Prevalence of hyperfibrinolysis in patients with liver cirrhosis . Fibrinolysis 1993;7:59.

23.

Violi F. , Ferro D. , Basili S. , et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993;17:78.,

24.

Boks AL , Brommer Ejp , Schalm SW , et al. Hemostasis and fibripolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986;6:79.

25.

Tran-Thang C. , Fasel-Felley J. , Pralong G. , et al. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989;62:651.

26.

Lasierra J. , Aza MJ , Vilades E. , et al. Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis . Fibrinolysis 1991;5:117.

27.

Griffin JH , Mosher DF , Zimmerman TS Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982 ;60:261.

28.

Mannucci PM , Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982;2:463.

29.

van Hinsbergh Vwm , Bertina RM , van Wijngaarden A. , et al. Activated protein C decreases plasminogen activator inhibitor activity in endothelial cell conditioned medium. Blood 1985;65:444.

30.

Kwaan HC , Barlow GH Nature and biological activities of degradation products of fibrinogen and fibrin. Annu Rev Med 1973;24:335.

31.

Pugh Rnh , Murray-Lyon IM , Dawson JL , Pietroni MC , Williams R. Transaction of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973:60:646.